ACTRN12617000186358Completed未知
Immunological Effects of Andrographis paniculata in healthy adult males
Integria Healthcare (Australia) Pty Ltd.0 sites20 target enrollmentStarted: February 3, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 70 Years (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 1
Study the effects of Andrographis paniculata on platelet aggregation in Thai healthy volunteers: the pilot studyhealthy human volunteersTCTR20141128001Faculty of Medicine Siriraj Hospital10
Not yet recruiting
Phase 4
A clinical study to understand the combined effects of Andrographis & metformin, in comparison to metformin alone treatment on glycemic control in type 2 diabetes patientsCTRI/2019/11/021977Dr Anand Kumar Maurya
Completed
Phase 3
The efficacy and safety of Andrographis paniculata extract for the treatment of acute nonspecific upper respiratory tract infections: a randomized double-blind placebo controlled trialAcute nonspecific upper respiratory tract infections with one or more symptoms such as fever,sore throat,nasal congestion,dry infrequent cough and had modified Centor Score of 2 or less.Andrographis paniculataandrographolideacute nonspecific upper respiratory tract infectionspharyngitiscommon coldTCTR20170329002Department of Thai Traditional and Alternative Medicine829
Completed
Phase 2
Efficacy of Andrographis paniculata spray in acute pharyngitisAcute viral pharyngitisAndrographis paniculata, acute viral pharyngitis, sore throat, plant extract, sprayTCTR20230915005Abhaiphubet Chaopraya Hospital Foundation60
Completed
Phase 2
Efficacy of Andrographis paniculata extract Combined with Favipiravir Treatment to Prevent Disease Progression in mild to moderate COVID-19 Patients: A Double-blind, Randomized, Placebo-Controlled StudyMild to moderate COVID-19andrographolides, COVID-19, SARS-CoV-2, andrographis panniculata, favipiravirTCTR20210609001Chulabhorn Royal Academy146